… in their lungs, a leading cause of COVID-19 mortality. This lung hyper-… inhibitors that are
being clinically evaluated and repurposed for the treatment of patients with severe COVID-19 …

… interleukins promote STAT3 activation via JAK2 and therefore the JAK2 inhibitors could …
reducing inflammation in COVID-19 patients [Citation87]. While the JAK inhibition may hamper …

… There is another ongoing registered randomized, parallel assignment, interventional trial
(NCT04404361), in which the efficacy and safety of Pacritinib, a selective JAK2 inhibitor, are …

… Nevertheless, no treatment of COVID-19 with tofacitinib has been reported to date. Baricitinib
is a selective JAK1/JAK2 inhibitor approved for the treatment of RA [18]. Both SARS-CoV-2 …

… Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and … -CoV-2 and the COVID-19
pandemic, and then focuses on … that have been reported in COVID-19 patients. The potential …

… In conclusion, we found a potential role for JAK-inhibitors in reducing the risk of death in
persons with COVID-19. The mechanism(s) underlying this benefit is unknown and when …

… Therefore, JAKi, and especially JAK1/JAK2 inhibitors, were suggested as a … in COVID-1984
because treatment with a JAK1/JAK2 inhibitor to prevent lung injury in severe COVID-19 …

… lower mortality in COVID-19. These efforts might benefit from specific JAK2 inhibitors with the
… noted that JAK inhibition is one of many treatment strategies for COVID-19 patients that are …

… state in COVID-19 by application of Janus kinase inhibitors. Ruxolitinib is one of the approved
… There are also miscellaneous reports indicating the benefits of JAK inhibitors in COVID-19 …

… inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common
cause of adverse clinical outcomes in COVID-19… JAK1 and JAK2 inhibitor COVID-19 Phase III…